ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLS
DOI:
https://doi.org/10.15407/exp-oncology.2025.02.156Keywords:
breast cancer, trastuzumab, HER2-positive, ascorbyl palmitate, apoptosis, ascorbic acid palmitateAbstract
Background. Breast cancer (BC) accounts for about 30% of cancers in women, with a mortality rate of around 15%. HER2- positive BC, an aggressive subtype, represents 15—20% of all BC cases. High-dose vitamin C has shown antitumor effects by increasing reactive oxygen species in cancer cells without significant toxicity. Aim. This study aimed to explore an in vitro dual treatment using ascorbyl palmitate (AP), a lipophilic vitamin C derivative, and trastuzumab, an HER2 receptor blocker. Materials and Methods. HER2-positive SK-BR-3 BC cells were treated with AP, trastuzumab, or their combination. The cell survival MTT assay, apoptosis, and cell cycle phase analysis were conducted using flow cytometry, while mRNA and protein expression were assessed using RT-qPCR and Western blot methods. Ki-67 expression was evaluated by immunofluorescence assay. Results. AP reduced cell viability in a time- and dose-dependent manner, and its combination with trastuzumab further decreased cell viability. A cytometric analysis showed enhanced apoptosis after combination treatment. mRNA analysis revealed upregulated TP53 mRNA expression, along with upregulation of BAX, CYCS, CASP3, and CASP8 gene expression, while the BCL-2 and BCL2L1 genes were downregulated, further supporting the induction of apoptosis. The antiproliferative effectiveness of the combination therapy was demonstrated by a Western blot assay, which showed suppression of phospho-P38, ERK1/2, and PI3K protein synthesis. Conclusion. These results underscore the potential effects of combining AP and trastuzumab in BC treatment, guiding future therapeutic strategies.
References
IARC. Estimated age-standardized incidence rates (World) in 2020, worldwide, both sexes, all ages. Accessed 30.07.2021, 2021. https://gco.iarc.fr/today/home
Tsang JYS, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol. 2020;27(1):27-35. https://doi. org/10.1097/PAP.0000000000000232
Godoy-Ortiz A, Sanchez-Munoz A, Chica Parrado MR, et al. Deciphering HER2 breast cancer disease: biological and clinical implications. Front Oncol. 2019;9:1124. https://doi.org/10.3389/fonc.2019.01124
Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clin. 2018;13(3):339-354. https:// doi.org/10.1016/j.cpet.2018.02.006
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemo- therapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205. https://doi.org/10.1016/S0140-6736(16)32616-2
Ghosh R, Narasanna A, Wang SE, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011;71(5):1871-1882. https://doi.org/10.1158/0008-5472.Can-10-1872
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. https://doi.org/10.1200/JCO.2013.50.9984
Fan Y, Li X, Zhong P, et al. Radiological features for predicting the status of cD8-positive lymphocytes in HER2 po- sitive breast cancer. Balkan Med J. 2024;41(3):213-221. https://doi.org/10.4274/balkanmedj.galenos.2024.2024-2-64
Fiszman GL, Jasnis MA. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer.
Int J Breast Cancer. 2011;2011:352182. https://doi.org/10.4061/2011/352182
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117-34. https://doi. org/10.1016/j.cell.2010.06.011
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137. https://doi.org/10.1038/35052073
Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol. 2019;59:125- 132. https://doi.org/10.1016/j.semcancer.2019.07.009
Pencik J, Pham HT, Schmoellerl J, et al. JAK-STAT signaling in cancer: From cytokines to non-coding genome.
Cytokine. 2016;87:26-36. https://doi.org/10.1016/j.cyto.2016.06.017
Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nature Rev Cancer. 2013;13(9):663-673. https://doi.org/10.1038/nrc3559
Zhou M, Li X, Li YY, et al. Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for syn- ergistic anti-tumoral therapy. Drug Deliv. 2017;24(1):1230-1242. https://doi.org/10.1080/10717544.2017.1370619
Mustafi S, Camarena V, Qureshi R, et al. Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy. Theranostics. 2021;11(8):3552-3564. https://doi.org/10.7150/thno.53225
Banks WA, Kastin AJ. Peptides and the blood-brain-barrier - lipophilicity as a predictor of permeability. Brain Res Bull. 1985;15(3):287-292. https://doi.org/10.1016/0361-9230(85)90153-4
Lee SJ, Jeong JH, Lee IH, et al. Effect of high-dose vitamin c combined with anti-cancer treatment on breast cancer cells. Anticancer Res. 2019;39(2):751-758. https://doi.org/10.21873/anticanres.13172
Gu X, Zhu D, Jiang Y, et al. Adoption of ultrasound-guided polymer nanocarriers in tumor chemoradiotherapy and oxidation treatment. Cell Mol Biol (Noisy-le-grand). 2023;69(2):138-143. https://doi.org/10.14715/cmb/2023.69.2.23
Naidu KA, Tang JL, Naidu KA, et al. Antiproliferative and apoptotic effect of ascorbyl stearate in human glioblas- toma multiforme cells: modulation of insulin-like growth factor-I receptor (IGF-IR) expression. J Neuro-Oncol. 2001;54(1):15-22. https://doi.org/10.1023/A:1012545311054
Kageyama K, Onoyama Y, Kimura M, et al. Enhanced inhibition of DNA-synthesis and release of membrane phospholipids in tumor-cells treated with a combination of acylated ascorbate and hyperthermia. Int J Hyperther. 1991;7(1):85-91. https://doi.org/10.3109/02656739109004979
Kalaycioglu GD. Preparation of magnetic nanoparticle integrated nanostructured lipid carriers for controlled deliv- ery of ascorbyl palmitate. MethodsX. 2020;7:101147. https://doi.org/10.1016/j.mex.2020.101147
Roomi MW, House D, Tsao CS. Cytotoxic effect of substitution at 2-, 6-, and 2,6-positions in ascorbic acid on ma- lignant cell line. Cancer Biochem Biophys. 1998;16(4):295-300.
Kato S, Asada R, Kageyama K, et al. Anticancer effects of 6-o-palmitoyl-ascorbate combined with a capacitive-resis- tive electric transfer hyperthermic apparatus as compared with ascorbate in relation to ascorbyl radical generation. Cytotechnology. 2011;63(4):425-435. https://doi.org/10.1007/s10616-011-9363-8
Guvenc A, Ustundag K, Yoruyus A, et al. Homoeriodictyol inhibits survival and migration of androgen-resistant prostate cancer cells in vitro. Exp Oncol. 2025;47(1):34-43. https://doi.org/10.15407/exp-oncology.2025.01.034
Erdogan S, Turkekul K, Dibirdik I, et al. Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-kappaB. Invest New Drugs. 2020;38(2):246-263. https://doi.org/10.1007/s10637-019-00774-8
Erdogan S, Serttas R, Dibirdik I, Turkekul K. Multifaceted impact of adipose conditioned media: Obesity-driven promotion of prostate cancer and cancer stem cell dynamics. Cell Biochem Funct. 2024;42(2):e3979. https://doi. org/10.1002/cbf.3979
Zhang Y, Han Y, Dong J, Li F, Sun Y. Asiaticoside down-regulates HIF-1alpha to inhibit proliferation, migration, and angiogenesis in thyroid cancer cells. Balkan Med J. 2024;41(1):23-29. https://doi.org/10.4274/balkanmedj.ga- lenos.2023.2023-7-123
Sawant RR, Vaze OS, Wang T, et al. Palmitoyl ascorbate liposomes and free ascorbic acid: comparison of anticancer therapeutic effects upon parenteral administration. Pharm Res-Dordr. 2012;29(2):375-383. https://doi.org/10.1007/ s11095-011-0557-8
Katharotiya K, Shinde G, Katharotiya D, et al. Development, evaluation and biodistribution of stealth liposomes of 5-fluorouracil for effective treatment of breast cancer. J Liposome Res. 2022;32(2):146-158. https://doi.org/10.1080
/08982104.2021.1905661
Li J, Guo C, Feng F, et al. Co-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumor efficacy. Sci Rep. 2016;6:38787. https://doi.org/10.1038/srep38787
Giordano SH, Temin S, Chandarlapaty S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(26):2736- 2740. https://doi.org/10.1200/JCO.2018.79.2697
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. Feb 19 2015;372(8):724-374. https://doi.org/10.1056/NEJMoa1413513
Maddox AL, Brehove MS, Eliato KR, et al. Molecular assessment of HER2 to identify signatures associated with ther- apy response in HER2-positive breast cancer. Cancers (Basel). 2022;14(11)https://doi.org/10.3390/cancers14112795
Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395-402. https://doi.org/10.1016/j. ccr.2007.08.030
Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117-127. https://doi.org/10.1016/j.ccr.2004.06.022
Nahta R, Takahashi T, Ueno NT, et al. P27 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64(11):3981-3986. https://doi.org/10.1158/0008-5472.Can-03-3900
Erdogan S, Turkekul K, Dibirdik I, et al. Midkine downregulation increases the efficacy of quercetin on pros- tate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway. Biomed Pharmacother. 2018;107:793-805. https://doi.org/10.1016/j.biopha.2018.08.061
Zhang H, Zhang L, He Y, et al. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett. 2024;598:217112. https://doi.org/10.1016/j.canlet.2024.217112
Khajah MA, Mathew PM, Luqmani YA. Inhibitors of PI3K/ERK1/2/p38 MAPK show preferential activity against endo- crine-resistant breast cancer cells. Oncol Res. 2017;25(8):1283-1295. https://doi.org/10.3727/096504017x14883245308282
Campone M, Noel B, Couriaud C, et al. c-Myc dependent expression of pro-apoptotic Bim renders HER2- overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol Cancer. 2011;10:110. https://doi. org/10.1186/1476-4598-10-110
Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repres- sion of Her2/neu (erbB-2) oncogene. Ann Oncol. 2005;16(8):1253-1267. https://doi.org/10.1093/annonc/mdi239
Schneider J, Jeon YW, Suh YJ, Lim ST. Effects of ruxolitinib and calcitriol combination treatment on various mo- lecular subtypes of breast cancer. Int J Mol Sci. 2022;23(5):2535. https://doi.org/10.3390/ijms23052535
Shabo I, Svanvik J, Lindstrom A, et al. Roles of cell fusion, hybridization and polyploid cell formation in cancer metastasis. World J Clin Oncol. 2020;11(3):121-135. https://doi.org/10.5306/wjco.v11.i3.121
Kute TE, Savage L, Stehle JR, Jr., et al. Breast tumor cells isolated from in vitro resistance to trastuzumab re- main sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother. 2009;58(11):1887-1896. https://doi.org/10.1007/s00262-009-0700-0
Mayer IA. Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer. 2009;9(Suppl 2):S50-S57. https://doi.org/10.3816/CBC.2009.s.005
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
